Seeking Alpha

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (RXRX) (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
Seeking Alpha

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an ...
Nasdaq

What Type Of Shareholders Make Up Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Registry?

The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ...
Business Wire

Recursion Signs Global Licensing Agreement with the Ohio State Innovation Foundation to Develop REC-2282 to Treat Neurofibromatosis Type 2

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a clinical-stage biotechnology company combining artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, ...